| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8946262 | CUBIST PHARMS | Methods of preventing and treating gastrointestinal dysfunction |
Feb, 2030
(6 years from now) | |
Entereg is owned by Cubist Pharms.
Entereg contains Alvimopan.
Entereg has a total of 1 drug patent out of which 0 drug patents have expired.
Entereg was authorised for market use on 20 May, 2008.
Entereg is available in capsule;oral dosage forms.
Entereg can be used as a method to accelerate the time to gastrointestinal recovery by administering about 12 mg of alvimopan to the patient from about 30 to 60 minutes prior to surgery.
The generics of Entereg are possible to be released after 12 February, 2030.
Drugs and Companies using ALVIMOPAN ingredient
Market Authorisation Date: 20 May, 2008
Treatment: A method to accelerate the time to gastrointestinal recovery by administering about 12 mg of alvimopan to the patient from about 30 to 60 minutes prior to surgery
Dosage: CAPSULE;ORAL
ENTEREG family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic